Alphyn Poster at American Academy of Dermatology Annual Meeting Highlights Potential of Zabalafin Hydrogel as Singular, Comprehensive Treatment for Atopic Dermatitis

Phase 2a clinical program demonstrates safety and efficacy for all endpoints in AD with and without secondary infection ANNAPOLIS, Md. and ORLANDO, Fla., March 10, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®,…